Masimo Corporation (MASI)
NASDAQ: MASI · Real-Time Price · USD
136.66
+0.94 (0.69%)
At close: Dec 18, 2025, 4:00 PM EST
136.66
0.00 (0.00%)
After-hours: Dec 18, 2025, 5:48 PM EST
Masimo Revenue
Masimo had revenue of $371.50M in the quarter ending September 27, 2025, with 8.21% growth. This brings the company's revenue in the last twelve months to $2.18B, up 38.48% year-over-year. In the year 2024, Masimo had annual revenue of $2.09B with 2.26% growth.
Revenue (ttm)
$2.18B
Revenue Growth
+38.48%
P/S Ratio
3.36
Revenue / Employee
$606,111
Employees
3,600
Market Cap
7.34B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 28, 2024 | 2.09B | 46.30M | 2.26% |
| Dec 30, 2023 | 2.05B | 12.30M | 0.60% |
| Dec 31, 2022 | 2.04B | 796.60M | 64.28% |
| Jan 1, 2022 | 1.24B | 95.50M | 8.35% |
| Jan 2, 2021 | 1.14B | 205.86M | 21.95% |
| Dec 28, 2019 | 937.84M | 79.55M | 9.27% |
| Dec 29, 2018 | 858.29M | 68.04M | 8.61% |
| Dec 30, 2017 | 790.25M | 95.62M | 13.77% |
| Dec 31, 2016 | 694.63M | 64.51M | 10.24% |
| Jan 2, 2016 | 630.11M | 43.47M | 7.41% |
| Jan 3, 2015 | 586.64M | 39.40M | 7.20% |
| Dec 28, 2013 | 547.25M | 54.01M | 10.95% |
| Dec 29, 2012 | 493.23M | 54.25M | 12.36% |
| Dec 31, 2011 | 438.99M | 33.58M | 8.28% |
| Jan 1, 2011 | 405.41M | 56.29M | 16.12% |
| Jan 2, 2010 | 349.12M | 42.04M | 13.69% |
| Jan 3, 2009 | 307.07M | 50.79M | 19.82% |
| Dec 29, 2007 | 256.29M | 31.95M | 14.24% |
| Dec 31, 2006 | 224.34M | 116.45M | 107.93% |
| Dec 31, 2005 | 107.89M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 435.16B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 64.24B |
| AbbVie | 59.64B |
| Eli Lilly and Company | 59.42B |
| AstraZeneca | 58.13B |
| Novartis AG | 56.37B |
| Novo Nordisk | 49.58B |
MASI News
- 7 days ago - Eight stock picks to play one of the healthiest corners of the market - Market Watch
- 13 days ago - HALPER SADEH LLC ENCOURAGES MASIMO CORPORATION SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS - PRNewsWire
- 14 days ago - Masimo Pitches 2028 Plan With 30% Operating Margins - Benzinga
- 14 days ago - Masimo Corporation (MASI) Analyst/Investor Day Transcript - Seeking Alpha
- 15 days ago - Masimo Hosts 2025 Investor Day and Details Strategic Roadmap for Durable Growth - Business Wire
- 4 weeks ago - Knobbe Martens Guides Masimo to $634M Win Against Apple in Patent Infringement Case - PRNewsWire
- 4 weeks ago - DRC Congratulates Knobbe Martens on its $634 Million Win for Masimo - GlobeNewsWire
- 4 weeks ago - Jury says Apple owes Masimo $634M for patent infringement - TechCrunch